GlaxoSmithKline: Influenza, Human trials

The registry lists 187 Influenza, Human studies with GlaxoSmithKline as lead sponsor. 3 are open to participants now and 132 have results posted.

Phase 1 25Phase 2 56Phase 3 74Phase 4 12No phase 23(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 YearsCompletedNCT00719043Phase 2Results posted
• Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 YearsCompletedNCT00718120Phase 3Results posted
• Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults.CompletedNCT00714285Phase 1Results posted
• A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ / Influsplit SSW® 2008/2009 in AdultsCompletedNCT00706563Phase 3Results posted
• A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64CompletedNCT00695669Phase 2Results posted
• Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With FluarixCompletedNCT00693706Phase 1Results posted
• Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination SchedulesCompletedNCT00652743Phase 3Results posted
• Non-inferiority Study of GSK Biologicals' Influenza Vaccine GSK576389A Using Different FormulationsCompletedNCT00633074Phase 2Results posted
• Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 YearsCompletedNCT00616928Phase 3Results posted
• A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged BulkCompletedNCT00586469Phase 4Results posted
• Revaccination With Influenza Vaccine GSK1247446ACompletedNCT00545025Phase 2Results posted
• Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389ACompletedNCT00540592Phase 2Results posted
• Study to Evaluate an Influenza Vaccine CandidateCompletedNCT00540228Phase 2Results posted
• Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly AdultsCompletedNCT00538473Phase 2Results posted
• Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly AdultsCompletedNCT00538213Phase 2Results posted
• Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and OverCompletedNCT00532298Phase 2Results posted
• Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly AdultsCompletedNCT00529516Phase 3Results posted
• Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in AdultsCompletedNCT00510874Phase 1Results posted
• Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed AdultsCompletedNCT00506350Phase 2Results posted
• Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in ChildrenCompletedNCT00502593Phase 2Results posted
• Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in AdultsCompletedNCT00449670Phase 3Results posted
• Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)CompletedNCT00430521Phase 2Results posted
• Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of AgeCompletedNCT00397215Phase 2Results posted
• Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine CandidateCompletedNCT00385840Phase 2Results posted
• Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in AdultsCompletedNCT00385255Phase 3Results posted
• Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in ChildrenCompletedNCT00383123Phase 3Results posted
• Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™CompletedNCT00377611Phase 4Results posted
• Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine CandidateCompletedNCT00374842Phase 2Results posted
• Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 YearsCompletedNCT00372255Phase 4Results posted
• Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine CandidateCompletedNCT00363077Phase 2Results posted
• Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an Adjuvanted Influenza Vaccine CandidateCompletedNCT00321763Phase 2Results posted
• Study to Evaluate an Influenza Vaccine CandidateCompletedNCT00321373Phase 2Results posted
• Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and AboveCompletedNCT00319098Phase 3Results posted
• Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly PopulationCompletedNCT00318149Phase 2Results posted
• Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly PopulationCompletedNCT00306995Phase 2Results posted
• A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and AboveCompletedNCT07204964Phase 2
• A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and OlderCompletedNCT07121192Phase 2
• A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older AdultsCompletedNCT06382311Phase 1/2
• An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza InfectionCompletedNCT04494412Phase 2
• Post-authorisation Safety Study (PASS) of Influenza Vaccine in United Kingdom (UK)CompletedNCT02567721
• Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administration in Healthy Chinese AdultsCompletedNCT02377401Phase 1
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of AgeWithdrawnNCT02177734Phase 1
• Drug Use Investigation for Arepanrix® (H1N1)CompletedNCT02069496
• Study to Assess the Burden of Mild Outcomes (Physician Office Visits) Due to Influenza in the United StatesCompletedNCT02019732
• FluLaval® Quadrivalent Pregnancy RegistryWithdrawnNCT02000466
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of AgeCompletedNCT01999842Phase 1
• Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of AgeCompletedNCT01934127Phase 1
• Assess the Risk of Solid Organ Transplant Rejection Following Vaccination With Pandemrix™ in UKCompletedNCT01715792
• Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of AgeCompletedNCT01659086Phase 1
• Influenza Burden Assessment in the United States, July1997 - up to April 2009CompletedNCT01599390
• Cost of Illness Associated With Influenza in the UKCompletedNCT01521416
• Influenza Burden Assessment in the United Kingdom, 1996-2008CompletedNCT01520935
• Safety of Inhaled Zanamivir in PregnancyCompletedNCT01462487
• Phase1 Study of GR121167, Single and Multiple Dose Study in Healthy Japanese MalesCompletedNCT01428479Phase 1
• A Systematic Review of Studies of the Effect of Influenza Vaccine Against Mismatched StrainsCompletedNCT01416597
• Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)CompletedNCT01390792
• Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy AdultsCompletedNCT01389479Phase 3
• Zanamivir Aqueous Solution Compassionate Use Program Retrospective Chart Review StudyCompletedNCT01353768
• A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy VolunteersCompletedNCT01353729Phase 1
• A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy VolunteersCompletedNCT01258530Phase 1
• Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years OldCompletedNCT01236040Phase 1
• Effectiveness of Flu Vaccination and Burden of Illness Among Community-dwelling Elderly With Influenza Like Illness in BrazilTerminatedNCT01171157
• Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) ExposureWithdrawnNCT01045564Phase 2
• Safety and Immune Response of One-Dose of Candidate H1N1 Influenza Vaccine GSK2340274A in AdultsWithdrawnNCT01008956Phase 2
• Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United KingdomCompletedNCT00996853
• Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 DaysCompletedNCT00989404Phase 1
• A Study for Evaluation of GSK Biologicals' Pandemic Influenza VaccineWithdrawnNCT00866580Phase 3
• Immuno & Reacto of TF Trivalent Influenza Split Vaccine 2003/04 or of Std Formulation Influsplit SSW®/Fluarix™ 2003/04CompletedNCT00731393Phase 3
• Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03CompletedNCT00731029Phase 3
• Immunogenicity and Safety of GSK Biologicals' FluLaval® TFCompletedNCT00727428Phase 1
• A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® VaccineCompletedNCT00505453Phase 3
• Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in People 18 Years Old or AboveCompletedNCT00476307Phase 3
• Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly AdultsCompletedNCT00386698Phase 2
• Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in ElderlyCompletedNCT00386113Phase 2
• Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older AdultsCompletedNCT00380211Phase 3
• Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult PopulationCompletedNCT00377585Phase 2
• A Study to Demonstrate the Efficacy of GSK Biologicals' Influenza Vaccine in AdultsCompletedNCT00363870Phase 4
• Study to Evaluate the Safety and Immunogenicity of Fluarix™ 2006/2007 in Adults Aged 18 Years or AboveCompletedNCT00345904Phase 3
• Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly PopulationCompletedNCT00318058Phase 1
• Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of AgeCompletedNCT00309647Phase 1
• Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 YearsCompletedNCT00309634Phase 1
• Incidence of Influenza, Downstream Complications of Influenza & Hospitalizations in Elderly Vaccinated With Fluarix™CompletedNCT00306982
• Annual Study for Fluarix RegistrationCompletedNCT00306943Phase 3
• Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and OverCompletedNCT00232947Phase 3
• Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o.Status unknownNCT00216242Phase 3
• Study Comparing the Immune Response of Fluarix and Fluzone Influenza VaccinesCompletedNCT00197288Phase 3
• Post-marketing Study to Evaluate the Efficacy of Influenza VaccineCompletedNCT00197223Phase 3